Literature DB >> 27613618

Disease-Toxicant Interactions in Parkinson's Disease Neuropathology.

Gunnar F Kwakye1, Rachael A McMinimy2, Michael Aschner3.   

Abstract

Human disease commonly manifests as a result of complex genetic and environmental interactions. In the case of neurodegenerative diseases, such as Parkinson's disease (PD), understanding how environmental exposures collude with genetic polymorphisms in the central nervous system to cause dysfunction is critical in order to develop better treatment strategies, therapies, and a more cohesive paradigm for future research. The intersection of genetics and the environment in disease etiology is particularly relevant in the context of their shared pathophysiological mechanisms. This review offers an integrated view of disease-toxicant interactions in PD. Particular attention is dedicated to how mutations in the genes SNCA, parkin, leucine-rich repeat kinase 2 (LRRK2) and DJ-1, as well as dysfunction of the ubiquitin proteasome system, may contribute to PD and how exposure to heavy metals, pesticides and illicit drugs may further the consequences of these mutations to exacerbate PD and PD-like disorders. Although the toxic effects induced by exposure to these environmental factors may not be the primary causes of PD, their mechanisms of action are critical for our current understanding of the neuropathologies driving PD. Elucidating how environment and genetics collude to cause pathogenesis of PD will facilitate the development of more effective treatments for the disease. Additionally, we discuss the neuroprotection exerted by estrogen and other compounds that may prevent PD and provide an overview of current treatment strategies and therapies.

Entities:  

Keywords:  Disease-toxicant interaction; Estrogen; Gene-environment interaction; Heavy metals; Illicit drugs; Neurodegeneration; Parkinson’s disease (PD); Pesticides

Mesh:

Substances:

Year:  2016        PMID: 27613618      PMCID: PMC5344789          DOI: 10.1007/s11064-016-2052-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  162 in total

Review 1.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

2.  Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice.

Authors:  D E Dluzen; J L McDermott; B Liu
Journal:  Neurotoxicol Teratol       Date:  1996 Sep-Oct       Impact factor: 3.763

Review 3.  Manganese and calcium transport in mitochondria: implications for manganese toxicity.

Authors:  C E Gavin; K K Gunter; T E Gunter
Journal:  Neurotoxicology       Date:  1999 Apr-Jun       Impact factor: 4.294

4.  α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.

Authors:  Dilshan S Harischandra; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Toxicol Sci       Date:  2014-11-21       Impact factor: 4.849

5.  Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Leanne J Cooper; Nigel J Fullwood; Mark J Gibson; Martin D Curran; Jennifer A Court; David M A Mann; Shu-ichi Ikeda; Mark R Cookson; John Hardy; David Allsop
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

6.  Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells.

Authors:  Kazuhiro Nakaso; Satoru Ito; Kenji Nakashima
Journal:  Neurosci Lett       Date:  2007-12-23       Impact factor: 3.046

Review 7.  Manganese neurotoxicity.

Authors:  Allison W Dobson; Keith M Erikson; Michael Aschner
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

8.  Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany.

Authors:  A Seidler; W Hellenbrand; B P Robra; P Vieregge; P Nischan; J Joerg; W H Oertel; G Ulm; E Schneider
Journal:  Neurology       Date:  1996-05       Impact factor: 9.910

9.  The PINK1/Parkin pathway regulates mitochondrial morphology.

Authors:  Angela C Poole; Ruth E Thomas; Laurie A Andrews; Heidi M McBride; Alexander J Whitworth; Leo J Pallanck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

10.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

View more
  4 in total

Review 1.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

2.  Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.

Authors:  Vinod Kumar; Deepali Singh; Brajesh Kumar Singh; Shweta Singh; Namrata Mittra; Rakesh Roshan Jha; Devendra Kumar Patel; Chetna Singh
Journal:  Mol Cell Biochem       Date:  2017-12-02       Impact factor: 3.396

3.  Effect of Alkaloid Extract from African Jointfir (Gnetum africanum) Leaves on Manganese-Induced Toxicity in Drosophila melanogaster.

Authors:  Ganiyu Oboh; Opeyemi Babatunde Ogunsuyi; Olatunde Isaac Awonyemi; Victor Ayomide Atoki
Journal:  Oxid Med Cell Longev       Date:  2018-12-30       Impact factor: 6.543

Review 4.  Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.

Authors:  Carla Ferreira; Catarina Almeida; Sandra Tenreiro; Alexandre Quintas
Journal:  Life (Basel)       Date:  2020-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.